<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491322</url>
  </required_header>
  <id_info>
    <org_study_id>2006-P-000430/18</org_study_id>
    <secondary_id>K23DK073356</secondary_id>
    <nct_id>NCT00491322</nct_id>
  </id_info>
  <brief_title>Vitamin D Deficiency, Insulin Resistance and FGF-23</brief_title>
  <official_title>Impact of Vitamin D Deficiency on Insulin Resistance and the Regulation of FGF-23</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to determine if treating vitamin D deficiency decreases
      insulin resistance and improves insulin secretion in healthy volunteers. Additionally, this
      project will investigate if treating vitamin D deficiency affects a new phosphate-regulating
      hormone called FGF-23.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D deficiency or hypovitaminosis D, defined as serum 25 hydroxyvitamin D &lt; or = 20
      ng/mL, is prevalent in several populations in the United States, specifically minorities and
      the elderly. Causes of vitamin D deficiency include lack of exposure to sunlight,
      malnutrition, and drugs that alter vitamin D metabolism and absorption.

      Vitamin D is an essential factor for many organ systems. Data suggest that vitamin D is
      required for normal insulin secretion by the pancreas. Specifically, animal studies
      demonstrate that treatment of vitamin D deficiency improves insulin secretion. In humans,
      there is less consensus about the impact of vitamin D deficiency on insulin resistance. In
      one study of middle-aged patients with Type 2 diabetes mellitus, no association was seen
      between serum 25 hydroxyvitamin D levels and a measure of insulin resistance. However, in a
      larger study of younger glucose tolerant subjects, serum 25 hydroxyvitamin D levels were
      associated with both insulin secretion and insulin resistance. These data suggest that
      treatment of vitamin D deficiency may delay or prevent the development of insulin resistance,
      and thus diabetes mellitus type 2. Repletion of this common vitamin deficiency could
      therefore have major public health implications for the prevention of diabetes mellitus.

      Fibroblast growth factor 23 (FGF-23) is a newly discovered phosphaturic hormone that is
      regulated by both dietary and serum phosphate. Hormonal regulation of FGF-23, however, is
      largely unknown. Recent data suggest that vitamin D plays an important role in the regulation
      of FGF-23. Some groups have shown that inactivation of the vitamin D receptor gene decreases
      serum FGF-23 levels in mice; administration of 1,25 dihydroxyvitamin D stimulates the
      transcription of the FGF-23 gene in vitro. Little is known, however, about the regulation of
      FGF-23 by vitamin D in humans.

      Phosphate is critical for bone mineralization, muscle function, signal transduction, and the
      creation and utilization of energy. Vitamin D deficiency can result in phosphate
      malabsorption, osteomalacia and increased risk of fractures. Enhanced understanding of the
      regulation of this new phosphate-regulating hormone, FGF-23, will advance the field of
      phosphate metabolism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibroblast Growth Factor 23 (FGF23) After 12 Weeks of Weekly Ergocalciferol 50000 Units</measure>
    <time_frame>12 weeks</time_frame>
    <description>Fibroblast growth factor 23 (FGF23) is a phosphate and vitamin D regulating hormone.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>Ergocalciferol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ergocalciferol 50000 international units once a week for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ergocalciferol Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo once a week for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ergocalciferol</intervention_name>
    <description>Ergocalciferol 50000 international units once a week for 12 weeks</description>
    <arm_group_label>Ergocalciferol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ergocalciferol placebo</intervention_name>
    <description>Ergocalciferol placebo once a week for 12 weeks</description>
    <arm_group_label>Ergocalciferol Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 45 yrs

          -  Serum 25-OHD &lt; or = 20 ng/mL

          -  At least 1 menses in the last 3 months (females) and normal serum testosterone (males)

        Exclusion Criteria:

          -  Significant cardiac, hepatic, oncologic, or psychiatric disease

          -  History of diabetes mellitus, malabsorption, kidney stones, or recent alcohol
             excess/abuse (15 drinks per week in the last month)

          -  Fasting glucose &gt; 126 mg/dl or 2 hour OGTT &gt; 200 mg/dl

          -  Use of medications known to affect serum phosphate levels including phosphate-binding
             antacids, sodium etidronate, calcitonin, excessive doses of vitamin D (&gt; 1000 units
             per day), excessive doses of vitamin A (&gt; 20,000 units/day), calcitriol, growth
             hormone, or anti-convulsants

          -  Use of metformin or insulin sensitizing agents

          -  Serum calcium &lt; 8 or &gt; 11 mg/dL, creatinine &gt; 1.5 mg/dL, or Hgb &lt; 11 gm/dL

          -  Liver function tests &gt; 2 times the upper limit of normal

          -  TSH &lt; 0.1 or &gt; 7 uU/mL

          -  WBC &lt; 2,000 or &gt; 15,000/cmm

          -  Platelet count &lt; 100,000 or &gt; 500,000/cum

          -  Hormone replacement therapy or testosterone use

          -  Urine uhCG positive (females), testosterone &lt; 270 ng/dL (males)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherri-Ann M Burnett-Bowie, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Burnett SM, Gunawardene SC, Bringhurst FR, JÃ¼ppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006 Aug;21(8):1187-96.</citation>
    <PMID>16869716</PMID>
  </reference>
  <reference>
    <citation>Burnett-Bowie SM, Mendoza N, Leder BZ. Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men. Bone. 2007 Apr;40(4):913-8. Epub 2006 Dec 8.</citation>
    <PMID>17157573</PMID>
  </reference>
  <results_reference>
    <citation>Burnett-Bowie SA, Leder BZ, Henao MP, Baldwin CM, Hayden DL, Finkelstein JS. Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. Clin J Am Soc Nephrol. 2012 Apr;7(4):624-31. doi: 10.2215/CJN.10030911. Epub 2012 Feb 2.</citation>
    <PMID>22300739</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2007</study_first_submitted>
  <study_first_submitted_qc>June 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <results_first_submitted>October 25, 2013</results_first_submitted>
  <results_first_submitted_qc>April 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 2, 2018</results_first_posted>
  <last_update_submitted>April 2, 2018</last_update_submitted>
  <last_update_submitted_qc>April 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Sherri-Ann M. Burnett-Bowie</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>Vitamin D deficiency</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Diabetes mellitus</keyword>
  <keyword>FGF-23</keyword>
  <keyword>FGF23</keyword>
  <keyword>Phosphate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were enrolled from 2006-2008. Subjects were healthy volunteers recruited from the community</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ergocalciferol Group</title>
          <description>Ergocalciferol 50000 international units once a week for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Matching placebo once a week for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>While 92 subjects were enrolled, 2 subjects, 1 in each group, were withdrawn from the study and their data never analyzed due to pregnancy that prevented initiation of the study drug and 6 week non-compliance with the study medication due to a non-related illness.</population>
      <group_list>
        <group group_id="B1">
          <title>Ergocalciferol Group</title>
          <description>Ergocalciferol 50000 international units once a week for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Matching placebo once a week for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="7"/>
                    <measurement group_id="B2" value="29" spread="9"/>
                    <measurement group_id="B3" value="28" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fibroblast Growth Factor 23 (FGF23) After 12 Weeks of Weekly Ergocalciferol 50000 Units</title>
        <description>Fibroblast growth factor 23 (FGF23) is a phosphate and vitamin D regulating hormone.</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ergocalciferol Group</title>
            <description>Participants receiving ergocalciferol 50000 units weekly for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Ergocalciferol Placebo Group</title>
            <description>Participants receiving matching ergocalciferol placebo weekly for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Fibroblast Growth Factor 23 (FGF23) After 12 Weeks of Weekly Ergocalciferol 50000 Units</title>
          <description>Fibroblast growth factor 23 (FGF23) is a phosphate and vitamin D regulating hormone.</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" spread="42"/>
                    <measurement group_id="O2" value="39" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 to 38 weeks</time_frame>
      <desc>Subjects were monitored during the12 weeks of the intervention at their baseline, week 4, week 8, and week 12 visits for adverse events. Subjects were counseled to contact us after study completion if they had any concerns. During the 26 weeks after study completion, no subject contact the investigative team with an adverse event or concern.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ergocalciferol Group</title>
          <description>Ergocalciferol 50,000 international units once a week for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Matching placebo once a week for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sherri-Ann M. Burnett-Bowie</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>6177245594</phone>
      <email>sburnett-bowie@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

